The Voxelotor Effect: Decreased Affinity for New Drugs for Sickle Cell Disease?
Voxelotor (OXBRYTA) was abruptly withdrawn from the global market in September 2024. Clinicians and patients were not prepared for this, and the sudden discontinuation has caused much consternation, uncertainty, and loss of trust.
Authors
- Russell E. Ware (ORCID: https://orcid.org/0000-0001-9582-0594)
- Charles T. Quinn (ORCID: https://orcid.org/0000-0002-2372-2175)
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- University of Cincinnati (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1002/pbc.31475
- Citations
- 4
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.75